lin-9 Antibody

What is LIN-9 protein and what are its main functions?

LIN-9, also known as BARA or TGS, is a 542 amino acid protein belonging to the lin9 family. It functions as a mammalian homolog of the C. elegans Lin-9 protein and is predominantly expressed in testis and thymus tissues. LIN-9 localizes to the nucleoplasm and serves as a critical component of the DREAM complex (also known as the LINC complex), which represses cell cycle-dependent genes. LIN-9 has tumor suppressor properties, associating with retinoblastoma protein (Rb) to inhibit DNA synthesis and regulate genes required for the G1/S cell cycle transition .

The protein has a calculated molecular weight of approximately 64 kDa, with observed molecular weights typically ranging between 55-65 kDa in experimental conditions. LIN-9 undergoes alternative splicing, resulting in three distinct isoforms that may have varying regulatory roles in cellular processes .

What types of LIN-9 antibodies are available for research applications?

Several types of LIN-9 antibodies are available for research, including both polyclonal and monoclonal variants with different properties:

These antibodies provide researchers with options depending on the specific experimental requirements, species of study, and desired applications .

What are the recommended dilutions and protocols for using LIN-9 antibody in Western blotting?

For Western blotting applications, LIN-9 antibody dilutions vary depending on the specific antibody used. The polyclonal antibody 17882-1-AP is recommended for use at dilutions between 1:1000-1:6000 for Western blot applications. The optimal dilution should be determined empirically for each experimental system to obtain the best results .

A general Western blot protocol for LIN-9 antibody includes:

• Sample preparation: Lyse cells or tissues in appropriate buffer containing protease inhibitors

• Protein quantification: Determine protein concentration for equal loading

• SDS-PAGE: Separate proteins based on molecular weight (LIN-9 is expected at 55-65 kDa)

• Transfer: Transfer proteins to nitrocellulose or PVDF membrane

• Blocking: Block with 5% non-fat milk or BSA in TBST

• Primary antibody incubation: Apply diluted LIN-9 antibody and incubate overnight at 4°C

• Washing: Wash membrane with TBST buffer

• Secondary antibody incubation: Apply appropriate HRP-conjugated secondary antibody

• Detection: Develop using chemiluminescence reagents

When analyzing Western blot results, researchers should expect to observe LIN-9 protein at approximately 55-65 kDa, though the exact band pattern may vary depending on the specific isoform expression in the sample being tested .

How can I optimize immunoprecipitation (IP) protocols using LIN-9 antibody?

For successful immunoprecipitation with LIN-9 antibody, the recommended antibody amount is 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate . To optimize IP protocols with LIN-9 antibody, follow these methodological steps:

• Lysate preparation:

  • Use fresh cells or tissues when possible

  • Lyse samples in non-denaturing buffer (e.g., RIPA or NP-40 buffer) with protease inhibitors

  • Clear lysates by centrifugation (14,000 × g for 10 minutes at 4°C)

• Pre-clearing step:

  • Incubate lysate with Protein A/G beads for 1 hour at 4°C

  • Remove beads by centrifugation to reduce non-specific binding

• Antibody binding:

  • Add 0.5-4.0 μg of LIN-9 antibody to pre-cleared lysate

  • Incubate overnight at 4°C with gentle rotation

• Immunoprecipitation:

  • Add fresh Protein A/G beads and incubate for 2-4 hours at 4°C

  • Collect beads by centrifugation and wash 3-5 times with cold lysis buffer

  • Elute proteins with SDS sample buffer by heating at 95°C for 5 minutes

• Analysis:

  • Separate proteins by SDS-PAGE and detect by Western blotting

  • Use appropriate controls, including IgG control and input sample

When optimizing the protocol, consider that LIN-9 has been successfully immunoprecipitated from HEK-293 cells as demonstrated in validation studies. Additionally, the choice between different antibody clones may affect IP efficiency, as shown in comparisons between mAb#1, mAb#6, and polyclonal antibodies .

What are the recommended approaches for studying LIN-9's role in the DREAM complex?

To investigate LIN-9's role in the DREAM complex, researchers can employ several complementary approaches:

• Co-immunoprecipitation (Co-IP):

  • Use LIN-9 antibody to precipitate the protein and its interacting partners

  • Probe for known DREAM complex components (E2F4, DP1, p130/p107, B-MYB)

  • Alternatively, perform reverse Co-IP using antibodies against other complex members

  • LIN-9 antibodies have been successfully used in Co-IP applications as evidenced in published studies

• Chromatin Immunoprecipitation (ChIP):

  • Use LIN-9 antibody to identify genomic binding sites

  • Analyze binding at cell cycle-regulated promoters

  • Compare binding patterns in different cell cycle phases

• Proximity Ligation Assay (PLA):

  • Detect in situ protein-protein interactions between LIN-9 and other DREAM components

  • Visualize subcellular localization of interactions

• Gene expression analysis:

  • Use RNA interference or CRISPR/Cas9 to deplete LIN-9

  • Analyze changes in cell cycle-regulated gene expression

  • Focus on genes regulated during G1/S transition

• Cell cycle synchronization experiments:

  • Synchronize cells at different cell cycle stages

  • Analyze changes in DREAM complex composition using LIN-9 antibody

  • Correlate with cell cycle progression

Research has shown that LIN-9 is essential for the transcriptional program at mitosis, and genetic studies in mice indicate its crucial role in development and as a potential tumor suppressor . When designing experiments, consider that LIN-9's interaction with the DREAM complex may be cell type-specific and cell cycle phase-dependent .

How can I differentiate between the three LIN-9 isoforms using antibodies?

Differentiating between the three LIN-9 isoforms requires careful consideration of antibody epitope location and experimental techniques:

• Antibody selection based on epitope:

  • The mAb#1 antibody recognizes an epitope within amino acids 54-85, making it specific for the long form of LIN-9

  • Verify whether your antibody recognizes all isoforms or is isoform-specific by reviewing the immunogen sequence information

• Western blot analysis:

  • LIN-9 isoforms have different molecular weights: approximately 62 kDa (long form), 54 kDa (short form), and 48 kDa (LIN-9Δ84)

  • Use gradient gels (6-12%) for better separation of closely sized isoforms

  • Extend running time to achieve clear band separation

  • Include positive controls for each isoform when available

• Recombinant protein controls:

  • Express recombinant versions of each isoform as standards

  • Use these as size references and antibody validation controls

• PCR-based confirmation:

  • Design primers specific to each isoform

  • Perform RT-PCR to confirm the expression of specific isoforms at mRNA level

  • Correlate protein detection with transcript expression

• Specificity validation:

  • Use lysates from cells overexpressing individual isoforms

  • Perform knockdown experiments targeting specific isoforms

  • Compare band patterns before and after manipulation

When interpreting results, note that the relative expression of LIN-9 isoforms may vary by tissue type, with testis and thymus showing predominant expression. The tissue-specific distribution of isoforms may have functional significance in different cellular contexts .

What are the implications of LIN-9 as a tumor suppressor and how can antibodies be used to investigate this function?

Research indicates that LIN-9 functions as a tumor suppressor, with heterozygous mice showing increased susceptibility to lung tumorigenesis induced by oncogenic c-Raf compared to wild-type mice . Researchers can investigate LIN-9's tumor suppressor functions using antibodies through several approaches:

• Tumor tissue analysis:

  • Compare LIN-9 expression levels in tumor versus normal tissues using immunohistochemistry (IHC) or Western blot

  • Correlate expression with tumor grade, stage, and patient outcomes

  • Examine co-localization with retinoblastoma protein (Rb) in tumor samples

• Signaling pathway investigation:

  • Use phospho-specific antibodies to examine post-translational modifications of LIN-9

  • Analyze LIN-9's interaction with tumor suppressor pathways using Co-IP

  • Investigate changes in cell cycle regulation following LIN-9 manipulation

• Genetic model systems:

  • Use LIN-9 antibodies to validate knockout or knockdown models

  • Confirm protein loss in LIN-9-deficient mice or cellular models

  • Analyze compensatory mechanisms in heterozygous models

• Cell proliferation and transformation assays:

  • Study LIN-9 expression and localization during oncogenic transformation

  • Correlate with changes in DNA synthesis using BrdU incorporation

  • Analyze cell cycle profiles in cells with altered LIN-9 levels

• G1/S transition regulation:

  • Investigate LIN-9's role in regulating genes required for G1/S transition

  • Use ChIP to identify direct targets regulated by LIN-9

  • Correlate with tumor-promoting gene expression patterns

When designing tumor-related studies, consider that LIN-9 appears to function as a haploinsufficient tumor suppressor, meaning that even partial reduction of its expression may contribute to tumorigenesis, particularly in the context of oncogenic driver mutations like c-Raf .

How can I troubleshoot inconsistent results when using LIN-9 antibody in immunofluorescence (IF) studies?

Immunofluorescence studies with LIN-9 antibody may present challenges due to the protein's nuclear localization and potential epitope masking. Here are methodological approaches to troubleshoot inconsistent results:

• Fixation method optimization:

  • Compare different fixatives (4% paraformaldehyde, methanol, or combination protocols)

  • Test varying fixation durations (10-20 minutes for PFA, 5-10 minutes for methanol)

  • For nuclear proteins like LIN-9, methanol fixation may improve nuclear epitope accessibility

• Permeabilization protocol refinement:

  • Test different permeabilization agents (0.1-0.5% Triton X-100, 0.1-0.5% Saponin)

  • Adjust permeabilization time (5-15 minutes)

  • For nuclear proteins, ensure sufficient permeabilization to access nuclear antigens

• Antibody validation controls:

  • Include LIN-9 knockdown/knockout cells as negative controls

  • Use cells with known high expression (testis or thymus-derived cell lines) as positive controls

  • Test multiple antibody clones if available (polyclonal vs. monoclonal)

• Signal amplification strategies:

  • Consider tyramide signal amplification for weak signals

  • Use biotin-streptavidin systems for enhanced detection

  • Optimize primary antibody incubation (overnight at 4°C vs. 1-2 hours at room temperature)

• Image acquisition optimization:

  • Adjust exposure settings to prevent saturation

  • Use appropriate filter sets to minimize autofluorescence

  • Consider confocal microscopy for improved nuclear signal resolution

• Protocol-specific considerations:

  • Block with 5-10% normal serum from the species of secondary antibody

  • Include 0.1-0.3% Triton X-100 in antibody dilution buffers

  • Use validated dilutions (start with manufacturer recommendations and titrate)

  • Consider antigen retrieval methods for formalin-fixed tissues

When interpreting results, remember that LIN-9 localizes primarily to the nucleoplasm and shows cell cycle-dependent expression patterns. Inconsistent staining might reflect biological variations rather than technical issues, particularly when examining asynchronous cell populations .

What considerations are important when investigating LIN-9's role in embryonic development using antibodies?

Investigating LIN-9's role in embryonic development presents unique challenges requiring specific methodological approaches:

• Developmental stage-specific analysis:

  • LIN-9 is essential for early mouse embryogenesis as evidenced by knockout studies

  • Consider temporal expression patterns during different developmental stages

  • Use stage-specific embryo collections for comparative analyses

• Antibody validation in embryonic tissues:

  • Confirm antibody specificity in embryonic lysates using Western blot

  • Include heterozygous and (when possible) knockout embryos as controls

  • Use alternative antibodies targeting different epitopes to confirm findings

• Immunohistochemistry (IHC) optimization for embryonic tissues:

  • Adjust fixation protocols for delicate embryonic tissues (shorter fixation times)

  • Optimize antigen retrieval methods specifically for embryonic samples

  • Consider vibratome or cryosectioning for better epitope preservation

• Co-localization studies:

  • Examine LIN-9 co-localization with developmental markers

  • Investigate interactions with other DREAM complex components during development

  • Analyze relationship with cell cycle regulators in developing tissues

• Technical considerations for embryonic samples:

  • Use microdissection to isolate specific embryonic structures when needed

  • Consider whole-mount immunofluorescence for early-stage embryos

  • Implement tissue clearing techniques for thick embryonic sections

• Experimental design for developmental studies:

  • Create conditional knockout models to bypass embryonic lethality

  • Use inducible systems (like tamoxifen-inducible Cre-loxP) as demonstrated in MEF studies

  • Develop tissue-specific knockdown approaches to study organ-specific functions

When interpreting results from embryonic samples, consider that LIN-9 expression patterns and protein interactions may differ significantly from adult tissues. Research has demonstrated that LIN-9 is essential for embryonic development, but the exact mechanisms and developmental time points of critical function require careful investigation using appropriate antibody-based techniques .

How should I analyze and interpret LIN-9 Western blot data that shows multiple bands?

Multiple bands in LIN-9 Western blots can result from various biological and technical factors. Here's a methodological approach to analyzing and interpreting such results:

• Expected LIN-9 banding patterns:

  • Primary band at 55-65 kDa representing full-length LIN-9

  • Possible isoform bands at approximately 62 kDa (long form), 54 kDa (short form), and 48 kDa (LIN-9Δ84)

  • Tissue-specific expression patterns may show different isoform distributions

• Distinguishing specific from non-specific bands:

  • Run appropriate controls including LIN-9 knockout/knockdown samples

  • Compare band patterns across different antibodies targeting different epitopes

  • Verify specificity using recombinant LIN-9 protein as a positive control

• Analysis of post-translational modifications:

  • Phosphorylation may cause slight upward shifts in apparent molecular weight

  • Consider phosphatase treatment to confirm phosphorylation-related bands

  • Other modifications (ubiquitination, SUMOylation) may result in higher molecular weight bands

• Assessment of degradation products:

  • Fresh sample preparation with protease inhibitors can minimize degradation

  • C-terminal degradation products may be detected by N-terminal-targeting antibodies

  • Compare fresh versus aged samples to identify potential degradation bands

• Technical troubleshooting for multiple bands:

  • Optimize antibody dilution to reduce non-specific binding

  • Increase wash stringency (higher salt concentration or detergent)

  • Consider gradient gels for better separation of closely sized isoforms

When interpreting results, remember that the observed molecular weight of LIN-9 typically ranges from 55-65 kDa , while the calculated molecular weight is approximately 64 kDa. These variations may reflect tissue-specific post-translational modifications or alternative splicing .

What controls should be included when validating LIN-9 antibody specificity for research applications?

Proper validation of LIN-9 antibody specificity requires a comprehensive set of controls:

• Genetic controls:

  • LIN-9 knockout or knockdown samples as negative controls

  • Heterozygous samples for partial expression reference

  • Overexpression systems as positive controls

  • Knockout validation has been demonstrated in research using MEFs with tamoxifen-inducible deletion of LIN-9

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide/protein

  • Compare signal with and without peptide blocking

  • Specific signals should be significantly reduced or eliminated

• Multiple antibody validation:

  • Test several antibodies targeting different epitopes

  • Compare signal patterns across antibodies (e.g., mAb#1, mAb#6, polyclonal)

  • Consistent detection across antibodies increases confidence in specificity

• Cross-species reactivity assessment:

  • Test antibody in samples from different species

  • Confirm reactivity matches manufacturer's claims (human, mouse, rat)

  • Consider evolutionary conservation of epitope regions

• Application-specific controls:

  • For WB: Include molecular weight markers and recombinant protein

  • For IF/IHC: Include primary antibody omission controls

  • For IP: Include IgG isotype controls

  • For ChIP: Include IgG controls and negative genomic regions

• Technical validation approaches:

  • Antibody titration to determine optimal concentration

  • Testing different blocking agents to minimize background

  • Batch-to-batch consistency testing for critical applications

When implementing these controls, document all validation steps carefully for publication and reproducibility purposes. Note that LIN-9 antibody 17882-1-AP has been cited in publications using Western blot, immunofluorescence, co-immunoprecipitation, and knockdown/knockout applications, providing precedent for these validation approaches .

How can I reconcile conflicting results between different experimental approaches when studying LIN-9 function?

Reconciling conflicting results when studying LIN-9 function requires systematic methodological approaches:

• Technical validation and standardization:

  • Ensure all antibodies are properly validated using controls described above

  • Standardize protein extraction methods across experiments

  • Maintain consistent experimental conditions (cell density, passage number)

  • Document lot numbers of antibodies used, as batch variation may contribute to discrepancies

• Cell type and context considerations:

  • LIN-9 function may vary between cell types due to different DREAM complex compositions

  • Expression is predominantly in testis and thymus, so other tissues may show different patterns

  • Cell cycle phase can dramatically affect LIN-9 interactions and function

  • Consider synchronized cells for more consistent results

• Isoform-specific analysis:

  • Different antibodies may preferentially detect specific isoforms

  • mAb#1 specifically recognizes amino acids 54-85, targeting the long form

  • Explicitly determine which isoforms are being detected in each experiment

  • Consider isoform-specific knockdown to isolate functions

• Complementary technique approach:

  • When WB and IF results conflict, consider native versus denatured protein conformations

  • Use orthogonal methods (e.g., mass spectrometry) to confirm protein identity

  • Employ molecular techniques (qRT-PCR) to correlate protein with mRNA levels

  • Consider chromatin fractionation to better assess nuclear protein dynamics

• Integrated data analysis strategies:

  • Perform meta-analysis across multiple experiments

  • Weight results based on control quality and technical reproducibility

  • Consider genetic background effects in animal models

  • Use statistical approaches to determine significance of observed differences

• Biological complexity considerations:

  • LIN-9's dual role in DREAM and MMB complexes may create context-dependent functions

  • As a tumor suppressor with embryonic lethality when knocked out, LIN-9 likely has essential and redundant functions

  • Cell cycle stage dramatically affects LIN-9 function and interactions

When reconciling conflicting results, consider that LIN-9 knockout causes embryonic lethality but heterozygosity predisposes to tumorigenesis, suggesting complex dosage-dependent functions . This biological complexity may explain apparently contradictory experimental outcomes observed with different techniques or in different cellular contexts.

What are the latest methodologies for studying LIN-9's role in the cell cycle using antibody-based approaches?

Recent advances in antibody-based techniques have expanded the toolkit for investigating LIN-9's cell cycle functions:

• Proximity labeling techniques:

  • BioID or TurboID fusion with LIN-9 to identify proximal interactors

  • APEX2-based proximity labeling for temporal interaction mapping

  • These approaches can capture transient interactions during different cell cycle phases

• Live-cell imaging approaches:

  • Fluorescently tagged nanobodies against LIN-9 for real-time imaging

  • FRET-based sensors to detect LIN-9 interactions with cell cycle regulators

  • These methods provide dynamic information about LIN-9 localization and complex formation

• Single-cell analysis techniques:

  • Combine immunofluorescence with cell cycle markers (EdU, PCNA, pH3)

  • Cyclic immunofluorescence (CyCIF) to simultaneously detect multiple proteins

  • Single-cell Western blotting for heterogeneity analysis

  • These approaches reveal cell-to-cell variation in LIN-9 expression and function

• Chromatin-focused methodologies:

  • CUT&RUN or CUT&Tag as alternatives to traditional ChIP

  • HiChIP to connect LIN-9 binding with chromatin architecture

  • These techniques provide higher resolution data on LIN-9's genomic interactions

• Multiplexed co-immunoprecipitation strategies:

  • Sequential immunoprecipitation to isolate specific LIN-9 subcomplexes

  • Mass spectrometry-based interactome analysis following immunoprecipitation

  • These approaches distinguish between DREAM and MMB complex components

• Genome editing validation systems:

  • CRISPR-Cas9 epitope tagging of endogenous LIN-9

  • Degradation tagging systems (AID, dTAG) for rapid protein depletion

  • These methods allow for cleaner experimental systems than traditional knockdown

Research has established LIN-9's essential role in mitotic gene regulation and embryonic development . These advanced methodologies enable more precise investigation of how LIN-9 contributes to cell cycle regulation through its participation in multi-protein complexes and how disruption of these functions may contribute to tumorigenesis.

How can researchers investigate the potential clinical relevance of LIN-9 as a tumor suppressor?

Investigating LIN-9's clinical relevance as a tumor suppressor requires multifaceted approaches combining antibody-based detection with other methodologies:

• Patient sample analysis:

  • Tissue microarray (TMA) analysis of LIN-9 expression across tumor types

  • Correlation of expression levels with clinical outcomes and staging

  • Co-expression analysis with other DREAM complex components

  • These approaches can identify cancer types where LIN-9 alterations are most relevant

• Genetic alteration correlation:

  • Compare LIN-9 protein levels with genomic data (mutations, copy number variations)

  • Analyze effects of LIN-9 heterozygosity in patient samples, as mouse models suggest haploinsufficiency can promote tumorigenesis

  • Investigate interaction with known oncogenic drivers (like c-Raf, which shows synergy with LIN-9 heterozygosity in mouse models)

• Functional biomarker development:

  • Develop antibody panels to assess DREAM complex integrity

  • Create phospho-specific antibodies to detect activation states

  • Establish immunohistochemistry (IHC) scoring systems for clinical application

• Therapeutic target investigation:

  • Study synthetic lethality relationships in LIN-9-deficient tumors

  • Examine cell cycle checkpoint dependencies in cells with altered LIN-9 levels

  • Investigate drug sensitivity correlations with LIN-9 expression patterns

• Experimental therapeutic models:

  • Evaluate LIN-9 restoration approaches in deficient models

  • Test combination therapies targeting pathways synergistic with LIN-9 loss

  • Develop patient-derived xenografts (PDXs) from tumors with LIN-9 alterations

• Clinical correlation methodologies:

  • Multivariate analysis of LIN-9 with clinical parameters

  • Machine learning approaches to identify patient subgroups based on LIN-9 and related markers

  • Longitudinal studies correlating LIN-9 with disease progression

When designing clinical studies, consider that LIN-9's role as a haploinsufficient tumor suppressor in lung cancer models suggests that even partial reduction in expression or function may be clinically significant, potentially making it a more sensitive biomarker than genes requiring complete inactivation.

What are the challenges in studying LIN-9 post-translational modifications and how can antibody-based approaches address them?

Studying LIN-9 post-translational modifications (PTMs) presents specific challenges that can be addressed through specialized antibody-based approaches:

• Challenges in PTM detection:

  • Low abundance of modified forms relative to total protein

  • Transient nature of many modifications during cell cycle

  • Multiple potential modification sites with possible interdependencies

  • Limited availability of PTM-specific antibodies for LIN-9

• Phosphorylation analysis strategies:

  • Phospho-specific antibody development targeting predicted sites

  • Phosphatase treatment controls to confirm phosphorylation-dependent bands

  • Phos-tag gels to enhance separation of phosphorylated forms

  • Mass spectrometry validation of specific phosphorylation sites

  • These approaches can map cell cycle-dependent phosphorylation events

• Ubiquitination and SUMOylation detection:

  • Denaturing immunoprecipitation to preserve ubiquitin linkages

  • Sequential immunoprecipitation (first for LIN-9, then for ubiquitin)

  • SUMO-trap constructs to enrich SUMOylated proteins

  • These methods can identify regulation through protein stability mechanisms

• Acetylation and methylation analysis:

  • Site-specific acetylation/methylation antibodies

  • HDAC/SIRT inhibitor treatment to enhance acetylation signals

  • Correlation with chromatin-modifying enzyme interactions

  • These approaches connect LIN-9 to epigenetic regulatory mechanisms

• Dynamic PTM profiling:

  • Synchronize cells and analyze modifications across the cell cycle

  • Compare modifications in normal versus tumor cells

  • Analyze effects of oncogene activation on LIN-9 PTM patterns

  • These methods reveal how PTMs may regulate LIN-9 function temporally

• Integrated PTM analysis:

  • Combine antibody-based detection with mass spectrometry

  • Cross-validate PTM sites using multiple methodologies

  • Map modification patterns to functional outcomes (complex formation, localization)

  • These integrative approaches provide more comprehensive PTM landscapes

When studying LIN-9 PTMs, researchers should consider that LIN-9's role in the DREAM complex and its function as a tumor suppressor suggest that its activity is likely tightly regulated through various modifications. Designing experiments that can capture these regulatory events will provide valuable insights into how LIN-9 function is modulated in different cellular contexts and how dysregulation may contribute to disease processes.